Serum Levels of TGF-β and Fibronectin in Autosomal Dominant Osteopetrosis in Relation to Underlying Mutations and Well-Described Murine Counterparts

Critical Reviews in Eukaryotic Gene Expression

Volumn 13, Issue 2-4 SPEC. ISS., 2003, Pages 163-171

  Bollerslev, Jens ^a,b   Ueland, Thor ^a   Odgren, Paul R ^c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Bone markers; LRP5; OPG; Osteoblasts; Osteoclasts

Indexed keywords

COLLAGEN; CROSS LINKED COLLAGEN; FIBRONECTIN; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; THYROID HORMONE; THYROTROPIN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ADULT; ALBERS SCHOENBERG DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOSOMAL DOMINANT DISORDER; BIOCHEMISTRY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MODEL; FEMALE; GENE; GENE MUTATION; HUMAN; HUMAN TISSUE; LRP5 GENE; MALE; MOUSE; NONHUMAN; OSSIFICATION; OSTEOLYSIS; PRIORITY JOURNAL; RAT; THYROTROPIN BLOOD LEVEL;

ADULT; ANIMALS; BONE AND BONES; COLLAGEN; DISEASE MODELS, ANIMAL; FEMALE; FIBRONECTINS; GENES, DOMINANT; GLIOMA; HEMOGLOBIN M; HUMANS; LDL-RECEPTOR RELATED PROTEINS; MALE; MICE; MIDDLE AGED; MUTATION; OSTEOCALCIN; OSTEOPETROSIS; RATS; RECEPTORS, LDL; SYNDROME; THYROID HORMONES; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA;

ANIMALIA; MURINAE;

EID: 0347624660     PISSN: 10454403     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevEukaryotGeneExpr.v13.i24.80     Document Type: Article

References (54)

1. Andersen PE Jr, Bollerslev J (1987): Heterogeneity of autosomal dominant osteopetrosis. Radiology 164: 223-225.
2. Benichou OD, Laredo JD, De Vernejoul MC (2000): Type II autosomal dominant osteopetrosis (Albers-Schonberg disease): clinical and radiological manifestations in 42 patients. Bone 26:87-93.
3. Bollerslev J (1989): Autosomal dominant osteopetrosis: bone metabolism and epidemiological, clinical, and hormonal aspects. Endocr Rev 10:45-67.
4. Bollerslev J (1995): Autosomal dominant osteopetrosis: bone metabolism and epidemiological, clinical and hormonal aspects: update 1995. Endocr Rev 4:365-373.
5. Bollerslev J, Andersen PE Jr (1989): Fracture patterns in two types of autosomal-dominant osteopetrosis. Acta Orthop Scand 60:110-112.
6. Bollerslev J, Marks SC Jr, Pockwinse S, Kassem M, Brixen K, Steiniche T, Mosekilde L (1993): Ultrastructural investigations of bone resorptive cells in two types of autosomal dominant osteopetrosis. Bone 14:865-869.
7. Bollerslev J, Mosekilde L, Nielsen HK, Mosekilde L (1989a): Biomechanical competence of iliac crest trabecular bone in autosomal dominant osteopetrosis type I. Bone 10: 159-164.
8. Bollerslev J, Steiniche T, Melsen F, Mosekilde L (1989b): Structural and histomorphometric studies of iliac crest trabecular and cortical bone in autosomal dominant osteopetrosis: a study of two radiological types. Bone 10: 19-24.
9. Bollerslev J, Thomas S, Grodum E, Brixen K, Djoseland O (1995): Collagen metabolism in two types of autosomal dominant osteopetrosis during stimulation with thyroid hormones. Eur J Endocrinol 133:557-563.
10. Bollerslev J, Ueland T, Grodum E, Haug E, Brixen K, Djoseland O (1998): Biochemical markers of bone metabolism in benign human osteopetrosis: a study of two types at baseline and during stimulation with triiodothyronine. Eur J Endocrinol 139:29-35.
11. Bollerslev J, Ueland T, Landaas S, Marks SC Jr (2000): Serum creatine kinase isoenzyme BB in mammalian osteopetrosis. Clin Orthop 377:241-247.
12. Boyden LM, Mao J, Belsky J, Mitzner L, Farhi A, Mitnick MA, Wu D, Insogna K, Lifton RP (2002): High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 346:1513-1521.
13. Brockstedt H, Bollerslev J, Melsen F, Mosekilde L (1996): Cortical bone remodeling in autosomal dominant osteopetrosis: a study of two different phenotypes. Bone 18: 67-72.
14. Centrella M, McCarthy TL, Canalis E (1988): Skeletal tissue and transforming growth factor beta. FASEB J 2: 3066-3073.
15. Chagraoui H, Komura E, Tulliez M, Giraudier S, Vainchenker W, Wendling F (2002): Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice. Blood 100:3495-3503.
16. Cielinski MJ, Marks SC Jr (1994): Understanding bone cell biology requires an integrated approach: reliable opportunities to study osteoclast biology in vivo. J Cell Biochem 56:315-322.
17. Cleiren E, Benichou O, Van Hul E, Gram J, Bollerslev J, Singer FR, Beaverson K, Aledo A, Whyte MP, Yoneyama T, deVernejoul MC, Van Hul W (2001): Albers-Schonberg disease (autosomal dominant osteopetrosis, type II) results from mutations in the ClCN7 chloride channel gene. Hum Mol Genet 10:2861-2867.
18. Desser L, Holomanova D, Zavadova E, Pavelka K, Mohr T, Herbacek I (2001): Oral therapy with proteolytic enzymes decreases excessive TGF-beta levels in human blood. Cancer Chemother Pharmacol 47(Suppl): S10-S15.
19. Dobbins DE, Sood R, Hashiramoto A, Hansen CT, Wilder RL, Remmers EF (2002): Mutation of macrophage colony stimulating factor (Csf1) causes osteopetrosis in the tl rat. Biochem Biophys Res Commun 294:1114-1120.
20. Felix R, Hofstetter W, Cecchini MG (1996): Recent developments in the understanding of the pathophysiology of osteopetrosis. Eur J Endocrinol 134:143-156.
21. Flanagan AM, Massey HM, Wilson C, Vellodi A, Horton MA, Steward CG (2002): Macrophage colony-stimulating factor and receptor activator NF-kappaB ligand fail to rescue osteoclast-poor human malignant infantile osteopetrosis in vitro. Bone 30:85-90.
22. Frattini A, Orchard PJ, Sobacchi C, Giliani S, Abinun M, Mattsson JP, Keeling DJ, Andersson AK, Wallbrandt P, Zecca L, Notarangelo LD, Vezzoni P, Villa A (2000): Defects in TCIRG1 subunit of the vacuolar proton pump are responsible for a subset of human autosomal recessive osteopetrosis. Nat Genet 25:343-346.
23. Globus RK, Doty SB, Lull JC, Holmuhamedov E, Humphries MJ, Damsky CH (1998): Fibronectin is a survival factor for differentiated osteoblasts. J Cell Sci 111(Pt 10):1385-1393.
24. Gong Y, Slee RB, Fukai N, Rawadi G, Roman-Roman S, Reginato AM, Wang H, Cundy T, Glorieux FH, Lev D, Zacharin M, Oexle K, Marcelino J, Suwairi W, Heeger S, Sabatakos G, Apte S, Adkins WN, Allgrove J, Arslan-Kirchner M, Batch JA, Beighton P, Black GC, Boles RG, Boon LM, Borrone C, Brunner HG, Carle GF, Dallapiccola B, De Paepe A, Floege B, Halfhide ML, Hall B, Hennekam RC, Hirose T, Jans A, Juppner H, Kim CA, Keppler-Noreuil K, Kohlschuetter A, LaCombe D, Lambert M, Lemyre E, Letteboer T, Peltonen L, Ramesar RS, Romanengo M, Somer H, Steichen-Gersdorf E, Steinmann B, Sullivan B, Superti-Furga A, Swoboda W, van den Boogaard MJ, Van Hul W, Vikkula M, Votruba M, Zabel B, Garcia T, Baron R, Olsen BR, Warman ML (2001): LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107:513-523.
25. Grainger DJ, Mosedale DE, Metcalfe JC (2000): TGF-beta in blood: a complex problem. Cytokine Growth Factor Rev 11:133-145.
26. Karsdal MA, Fjording MS, Foged NT, Delaisse JM, Lochter A (2001): Transforming growth factor-beta-induced osteoblast elongation regulates osteoclastic bone resorption through a p38 mitogen-activated protein kinase- and matrix metalloproteinase-dependent pathway. J Biol Chem 276:39350-39358.
27. Kornak U, Kasper D, Bosl MR, Kaiser E, Schweizer M, Schulz A, Friedrich W, Delling G, Jentsch TJ (2001): Loss of the ClC-7 chloride channel leads to osteopetrosis in mice and man. Cell 104:205-215.
28. Kornak U, Schulz A, Friedrich W, Uhlhaas S, Kremens B, Voit T, Hasan C, Bode U, Jentsch TJ, Kubisch C (2000): Mutations in the a3 subunit of the vacuolar H(+)-ATPase cause infantile malignant osteopetrosis. Hum Mol Genet 9:2059-2063.
29. Little RD, Carulli JP, Del Mastro RG, Dupuis J, Osborne M, Folz C, Manning SP, Swain PM, Zhao SC, Eustace B, Lappe MM, Spitzer L, Zweier S, Braunschweiger K, Benchekroun Y, Hu X, Adair R, Chee L, FitzGerald MG, Tulig C, Caruso A, Tzellas N, Bawa A, Franklin B, McGuire S, Nogues X, Gong G, Allen KM, Anisowicz A, Morales AJ, Lomedico PT, Recker SM, Van Eerdewegh P, Recker RR, Johnson ML (2002): A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet 70:11-19.
30. Marks SC Jr (1973): Pathogenesis of osteopetrosis in the ia rat: reduced bone resorption due to reduced osteoclast function. Am J Anat 138:165-189.
31. Marks SC Jr (1976): Osteopetrosis in the IA rat cured by spleen cells from a normal littermate. Am J Anat 146: 331-338.
32. Marks SC Jr (1977a): Osteopetrosis in the toothless (t1) rat: presence of osteoclasts but failure to respond to parathyroid extract or to be cured by infusion of spleen or bone marrow cells from normal littermates. Am J Anat 149:289-297.
33. Marks SC Jr (1977b): Pathogenesis of osteopetrosis in the microphthalmic mouse: reduced bone resorption. Am J Anat 149:269-275.
34. Marks SC Jr (1994): Osteopetrosis. Curr Opin Orthop 5:39-42.
35. Moursi AM, Damsky CH, Lull J, Zimmerman D, Doty SB, Aota S, Globus RK (1996): Fibronectin regulates calvarial osteoblast differentiation. J Cell Sci 109(Pt 6):1369-1380.
36. Noda M (1989): Transcriptional regulation of osteocalcin production by transforming growth factor-beta in rat osteoblast-like cells. Endocrinology 124:612-617.
37. Noda M, Rodan GA (1987): Type beta transforming growth factor (TGF beta) regulation of alkaline phosphatase expression and other phenotype-related mRNAs in osteoblastic rat osteosarcoma cells. J Cell Physiol 133: 426-437.
38. Oreffo RO, Mundy GR, Seyedin SM, Bonewald LF (1989): Activation of the bone-derived latent TGF beta complex by isolated osteoclasts. Biochem Biophys Res Commun 158:817-823.
39. Potts JR, Campbell ID (2003): Fibronectin structure and assembly. Curr Opin Cell Biol 6:648-655.
40. Quinn JM, Itoh K, Udagawa N, Hausler K, Yasuda H, Shima N, Mizuno A, Higashio K, Takahashi N, Suda T, Martin TJ, Gillespie MT (2001): Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions. J Bone Miner Res 16:1787-1794.
41. Rameshwar P, Chang VT, Thacker UF, Gascon P (1998): Systemic transforming growth factor-beta in patients with bone marrow fibrosis-pathophysiological implications. Am J Hematol 59:133-142.
42. Santos FR, Moyses RM, Montenegro FL, Jorgetti V, Noronha IL (2003): IL-1beta, TNF-alpha, TGF-beta, and bFGF expression in bone biopsies before and after parathyroidectomy. Kidney Int 63:899-907.
43. Seifert MF, Popoff SN, Jackson ME, MacKay CA, Cielinski M, Marks SC Jr (1993): Experimental studies of osteopetrosis in laboratory animals. Clin Orthop 294:23-33.
44. Shalhoub V, Jackson ME, Paradise C, Stein GS, Lian JB, Marks SC Jr (1996): Heterogeneity of colony stimulating factor-1 gene expression in the skeleton of four osteopetrotic mutations in rats and mice. J Cell Physiol 166:340-350.
45. Sly WS, Hewett-Emmett D, Whyte MP, Yu YS, Tashian RE (1983): Carbonic anhydrase II deficiency identified as the primary defect in the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification. Proc Natl Acad Sci U S A 80:2752-2756.
46. Stoker DJ (2002): Osteopetrosis. Semin Musculoskelet Radiol 6:299-306.
47. Takai H, Kanematsu M, Yano K, Tsuda E, Higashio K, Ikeda K, Watanabe K, Yamada Y (1998): Transforming growth factor-beta stimulates the production of osteoprotegerin/ osteoclastogenesis inhibitory factor by bone marrow stromal cells. J Biol Chem 273:27091-27096.
48. Tang CH, Yang RS, Liou HC, Fu WM (2003): Enhancement of fibronectin synthesis and fibrillogenesis by BMP-4 in cultured rat osteoblast. J Bone Miner Res 18:502-511.
49. Ueland T, Bollerslev J, Godang K, Muller F, Froland SS, Aukrust P (2001): Increased serum osteoprotegerin in disorders characterized by persistent immune activation or glucocorticoid excess-possible role in bone homeostasis. Eur J Endocrinol 145:685-690.
50. Van Wesenbeeck L, Cleiren E, Gram J, Beals RK, Benichou O, Scopelliti D, Key L, Renton T, Bartels C, Gong Y, Warman ML, De Vemejoul MC, Bollerslev J, Van Hul W (2003): Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density. Am J Hum Genet 72:763-771.
51. Van Wesenbeeck L, Odgren PR, MacKay CA, D'Angelo M, Safadi FF, Popoff SN, Van Hul W, Marks SC Jr (2002): The osteopetrotic mutation toothless (tl) is a loss-of-function frameshift mutation in the rat Csf1 gene: evidence of a crucial role for CSF-1 in osteoclastogenesis and endochondral ossification. Proc Natl Acad Sci U S A 99:14303-14308.
52. Whyte MP (1993): Osteopetrosis and the heritable forms of rickets. In Royce PM, Steinmann B (eds): Connective tissue and its heritable disorders. New York: Wiley-Liss.
53. Wilson CJ, Vellodi A (2000): Autosomal recessive osteopetrosis: diagnosis, management, and outcome. Arch Dis Child 83:449-452.
54. Yoshida H, Hayashi S, Kunisada T, Ogawa M, Nishikawa S, Okamura H, Sudo T, Shultz LD, Nishikawa S (1990): The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature 345:442-444.